Agenus Inc.

Day range

$6.14 – $6.50

Open

$6.49

Prev close

$6.33

Volume

687.56K

Market cap

$285.87M

Shares out

45.16M

P/E

3.11

P/S

2.15

P/B

-1.44

P/FCF

—

ROE

-46.1%

ROA

53.2%

Debt/Equity

-0.15

Div yield

0.00%

As of Oct 23, 2026

• Credit facilityAug 18, 2026

  On August 12, 2026, Agenus West, LLC (the "Borrower"), a subsidiary of Agenus Inc. (the "Company"), and the Company, as guarantor, entered into a Second Loan Modification Agreement (the "Loan Modification Agreement") with Ocean 1181 LLC (the "Lender") relating to the promissory note previously entered into with the Lender on November 26, 2024, as previously amended and restated... the outstanding principal amount remains $24,750,000, the maturity date was extended to November 30, 2029, and the loan bears interest at 13.0% per annum through maturity.

• Executive compensation changeAug 13, 2026

  On August 10, 2026, the Compensation Committee of the Board of Directors of Agenus Inc. approved a special, one-time performance-based stock option award to Garo H. Armen, Ph.D., the Company's Chairman and Chief Executive Officer, under and subject to the Company's Amended and Restated 2019 Equity Incentive Plan. The award consists of 1,971,500 performance-based stock options with a 10-year term.

• Director appointmentAug 11, 2026

  On August 5, 2026, the board of directors (the "Board") of Agenus Inc., a Delaware corporation (the "Company"), increased the size of the Board from six (6) to seven (7) directors and appointed Marco Tullio Marcucci to fill the resulting vacancy as a Class II director, to serve until the Company's 2029 annual meeting of stockholders and until his successor is duly elected and qualified, effective immediately. Mr. Marcucci was also appointed to serve as a member of the Board's Corporate Governance and Nominating Committee.

• Strategic initiativeJul 13, 2026

  On July 13, 2026, in connection with the Private Placement, the Company announced that it will conduct a strategic prioritization of botensilimab and balstilimab ("BOT+BAL") for the neoadjuvant treatment of microsatellite-stable ("MSS") colon cancer, including the advancement of ROBBIN, the Company's planned registrational Phase 3 neoadjuvant trial in MSS colon cancer.

• Warrant or conversionJul 6, 2026

  issued to certain of such noteholders 2026 D Warrants to purchase an aggregate of 56,525 shares of the Common Stock at exercise price of $3.25 per share and expiring on June 25, 2031 (the 'New D Warrants'); provided that the shares of Common Stock issuable upon exercise of the New D Warrants will be registered for resale with the SEC within ninety (90) days after June 29, 2026

Days to cover

5.7

Short interest

6.82M

Avg volume

1.21M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight
  positiveGlobeNewswire Inc.· Oct 26, 2026
• CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type
  positiveGlobeNewswire Inc.· Feb 18, 2026
• Agenus (AGEN) Q3 2024 Earnings Call Transcript
  neutralThe Motley Fool· Jan 5, 2026
• FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
  positiveBenzinga· Aug 28, 2025
• PD-(L)1 Inhibitors Market Set to Surge During the Forecast Period (2025–2034) as Immuno-Oncology Therapies Gain Momentum | DelveInsight
  positiveGlobeNewswire Inc.· Aug 18, 2025